Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis
Jie Song,1 Yue-Qin Xue,2 Ming-Ming Zhao,3 Peng Xu1 1Department of Neurosurgery, Linyi Central Hospital, Linyi, People’s Republic of China; 2Department of Pharmacy, Linyi Central Hospital, Linyi, People’s Republic of China; 3Department of Cardiology, Linyi Central Hospital, Linyi...
Main Authors: | Song J, Xue YQ, Zhao MM, Xu P |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-06-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/effectiveness-of-lomustine-and-bevacizumab-in-progressive-glioblastoma-peer-reviewed-article-OTT |
Similar Items
-
Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis
by: Xing Ren, et al.
Published: (2021-01-01) -
Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status
by: Matthias Schneider, et al.
Published: (2021-02-01) -
Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis
by: Nagham Kaka, et al.
Published: (2019-11-01) -
Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
by: Sunit Das, et al.
Published: (2020-01-01) -
The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis
by: Liao KL, et al.
Published: (2018-06-01)